NASDAQ$IMVT
Immunovant Inc · Q2 2025 earnings
Q2 2025 earnings · · Investor relations
Briefing
Reported development updates and financial results.
Immunovant reported its fiscal second quarter results, highlighting the advancement of IMVT-1402 with five IND applications cleared and progress in clinical trials for batoclimab. The company is on track to initiate multiple potentially registrational trials by March 31, 2025, and anticipates initiating clinical trials evaluating IMVT-1402 in a total of ten indications by March 31, 2026.
- Five Investigational New Drug (IND) applications were cleared across a range of therapeutic areas for lead asset, IMVT-1402.
- Proof of concept data from batoclimab trial in Graves’ disease (GD) demonstrate potential of deeper IgG reduction.
- IND cleared for IMVT-1402 in rheumatoid arthritis (RA), with potential best-in-class profile in difficult-to-treat (D2T) RA.
- Batoclimab trials in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) fully enrolled to support data disclosures by March 31, 2025.
Headline financials
Revenue & EPS history
Immunovant · Revenue · Quarterly
$0
Forward guidance
Immunovant is focused on advancing IMVT-1402 and batoclimab through clinical development across a broad range of indications. The company anticipates initiating multiple potentially registrational trials with IMVT-1402 and expects data readouts from batoclimab trials.
Tailwinds
- On track to initiate potentially registrational trials with IMVT-1402 in four to five indications by March 31, 2025.
- Anticipates initiating clinical trials evaluating IMVT-1402 in a total of ten indications by March 31, 2026.
- IMVT-1402 in GD has the potential to transform the treatment of GD patients who respond poorly to ATDs.
- IMVT-1402 can deliver meaningful clinical benefit in ACPA-positive (ACPA+) D2T RA patients, with a potentially best-in-class profile driven by deeper IgG reduction.
- Enrollment of study participants has completed in the Phase 2b trial evaluating batoclimab in chronic inflammatory demyelinating polyneuropathy (CIDP) for those patients to be included in the period 1 data readout expected by March 31, 2025.
Headwinds
- Competition for clinical trial participants with acute, active TED has increased.
- Top-line results for batoclimab in TED are now expected in the second half of calendar year 2025.
- Decision to enroll additional patients in the batoclimab CIDP study will be made following the readout of period 1 data.
- Future clinical trials may not confirm any safety, potency, or other product characteristics described or assumed in this press release.
- Any product candidate that Immunovant develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2025
+0.6%
Avg return
Earnings day
-0.6%
Avg return
5 days after
+3.3%
Avg return
30 days after
54%
15 / 28 earnings
Positive
+35.1%
Q4 2027
Best reaction
-34.6%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2027 | +35.1% | +29.9% | +34.5% | |
| Q3 2026 | +12.4% | +7.8% | +10.8% | |
| Q2 2026 | +0.0% | +1.7% | +0.9% | |
| Q1 2026 | -4.5% | -1.6% | +4.8% | |
| Q4 2025 | -0.2% | +3.0% | +8.1% | |
| Q3 2025 | -9.6% | -14.1% | -11.1% | |
| Q2 2025 | -2.5% | -6.8% | -8.9% | |
| Q1 2025 | +1.0% | +9.4% | +25.9% | |
| Q4 2024 | -7.1% | -11.3% | -7.1% | |
| Q3 2024 | +4.0% | +4.6% | -10.4% | |
| Q2 2024 | -2.3% | +4.7% | +17.4% | |
| Q1 2024 | +7.4% | -1.9% | +11.5% | |
| Q4 2023 | +4.9% | -0.8% | -5.1% | |
| Q3 2023 | +0.7% | +2.0% | -6.9% | |
| Q2 2023 | +6.3% | -2.1% | +23.2% | |
| Q1 2023 | +19.4% | +24.7% | +23.7% | |
| Q4 2022 | -12.6% | -20.4% | +0.2% | |
| Q3 2022 | -2.7% | -2.5% | -8.8% | |
| Q2 2022 | +1.1% | -0.3% | -12.8% | |
| Q1 2022 | +4.4% | +1.7% | +15.5% | |
| Q4 2021 | -34.6% | -34.5% | -25.0% | |
| Q3 2021 | -13.6% | -18.6% | -25.0% | |
| Q2 2021 | +3.1% | +7.3% | -4.0% | |
| Q1 2021 | +3.7% | +2.3% | +40.2% | |
| Q4 2020 | -11.0% | -13.5% | -14.2% | |
| Q3 2020 | +12.5% | +13.2% | +1.3% | |
| Q2 2020 | +0.1% | +0.1% | +13.9% | |
| Q1 2020 | +0.0% | +0.0% | +0.6% | |
| Q3 2019 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro